Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 4/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.37 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.37 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21085053 | 0.87 | KDM5A (0.42) | KDM5APHF8KDM2AKDM4CKDM7A | |
| SCHEMBL8920891 | 0.83 | KDM5A (0.47) | KDM5APHF8KDM2AKDM4CKDM7A | |
| SCHEMBL672141 | 0.83 | KDM5A (0.47) | KDM5APHF8KDM2AKDM4CKDM7A | |
| SCHEMBL301024 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL8026839 | 0.80 | — | — | |
| Bromide SCHEMBL15821114 | 0.80 | KDM5A (0.46) | KDM5APHF8KDM2AKDM4CKDM7A | |
| Water SCHEMBL15822499 | 0.80 | KDM5A (0.46) | KDM5APHF8KDM2AKDM4CKDM7A | |
| SCHEMBL21085160 | 0.79 | LMNA (0.37) | KDM5APHF8KDM2AKDM4CLMNA | |
| SCHEMBL2800 | 0.78 | HPGD (0.52) | KDM5APHF8KDM2AKDM4CLMNA | |
| SCHEMBL1009256 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | claimed |
| EP-1740587-A4 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS LLC (US) | 2009-07-15 | — | — | EP | claimed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | claimed |
| US-7217702-B2 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2007-05-15 | — | — | US | claimed |
| EP-1740587-A2 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | Adenosine Therapeutics, LLC (US) | 2007-01-10 | — | — | EP | claimed |
| US-20050282831-A1 | Selective antagonists of A2A adenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2005-12-22 | — | — | US | claimed |
| WO-2005097140-A2 | SELECTIVE ANTAGONISTS OF A2A ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2005-10-20 | — | — | WO | claimed |
| CN-1047778-C | Pyrimido [5-4-d] pyrimidines, drugs containing these compounds, their use and process for preparing them | THOMAE GMBH DR K (DE) | 1999-12-29 | — | — | CN | claimed |
| EP-0779888-B1 | PYRIMIDO [5,4-D]PYRIMIDINES, DRUGS CONTAINING THESE COMPOUNDS, THEIR USE, AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM PHARMA (DE) | 1999-04-28 | — | — | EP | claimed |
| US-5707989-A | ANTITUMOR AGENTS, INHIBITING SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | DR. KARL THOMAE GMBH (DE) | 1998-01-13 | — | — | US | claimed |
| EP-0567967-B1 | Tritium-labelled fibrinogen-receptor-antagonists, their use and their production | THOMAE GMBH DR K (DE) | 1996-07-10 | — | — | EP | claimed |
| EP-0567967-A1 | Tritium-labelled fibrinogen-receptor-antagonists, their use and their production | Dr. Karl Thomae GmbH (DE) | 1993-11-03 | — | — | EP | claimed |
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-1740587-A4 | SELECTIVE ANTAGONISTS OF A-2A- ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-5707989-A | ANTITUMOR AGENTS, INHIBITING SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | DR. KARL THOMAE GMBH (DE) | 1998-01-13 | — | — | US | disclosed |
| US-5677466-A | TESTING USING A AMIDINOPHENYL CONTAINING COMPOUND | DR. KARL THOMAE, GMBH (DE) | 1997-10-14 | — | — | US | disclosed |
| EP-0567967-B1 | Tritium-labelled fibrinogen-receptor-antagonists, their use and their production | THOMAE GMBH DR K (DE) | 1996-07-10 | — | — | EP | disclosed |
| EP-0567967-A1 | Tritium-labelled fibrinogen-receptor-antagonists, their use and their production | Dr. Karl Thomae GmbH (DE) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282831-A1 | Selective antagonists of A2A adenosine receptors | ADORA2A, ADORA2B, ADORA3 | KDM5A 3751/4885PHF8 4785/4885KDM2A 2767/4885 |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | KDM5A 2742/4885PHF8 3778/4885KDM2A 3678/4885 |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | GPR119, IAPP, DPP4 | KDM5A 3710/4885PHF8 4288/4885KDM2A 3456/4885 |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | KDM5A 1923/4885PHF8 4364/4885KDM2A 1823/4885 |
| US-10759749-B2 | Therapeutic agent for diabetes | GPR119, IAPP, DPP4 | KDM5A 2668/4885PHF8 3596/4885KDM2A 2495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.